News – March 2023
AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development.
Now it is also available to the contract manufacturing market: manufacturing virus and recombinant protein.
Some of our ongoing projects:
- HEK293 cell line: Identify integrations sites for induced expression of Rep protein
- CHO cell line:
- Identifying preferred/optimal integration sites
- Lower copy numbers
- Improved titers
- More stability
- Improved regulatory profile
- CHO promoter: Meanwhile Annogen is applying is SuRE™ technology to identify CHO derived promoter/enhancer with the goal to replace the commonly used and market standard CMV and EF1a promoters.
Please get in touch for more information and how we can help you improve your preferred cell lines.
